Artivion, Inc.
AORTHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, Artivion, Inc. (AORT) is listed under Medical Devices. With a market capitalization of $1.14B, it sits in small-cap territory. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system.
Market Cap
$1.14B
Beta
1.22
P/E (TTM)
—
P/E (Fwd)
31.14
EPS (TTM)
$-0.07
EPS (Fwd)
$0.75
ROE
-0.7%
ROA
2.6%
Cash
$77.3M
Total Debt
$408.0M
Free CF
$13.1M
52W Change
-47.9%
Annual Financials
Cash vs Debt
Where AORT stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, AORT finished 19.78% below its 150-day moving average ($27.15) and 28.47% below its 200-day moving average ($30.45). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AORT overbought or oversold?
At the October 19, 2026 close, AORT's RSI(14) was 37.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $77.3M in cash, though total debt stands at $408.0M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $13.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -0.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.6% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $313.8M (2022) to $441.3M (2025), reflecting a 41% increase over the period.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Artivion, Inc.'s trajectory.